Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
73.00    -0.50 (-0.68%)
Bid:
72.00
Ask:
74.00
Spread: 2.00 (2.778%)
Market Cap: £342.04m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Director Shareholding

10 Apr 2007 11:59

Avacta Group plc ("Avacta" or the "Company") Directors' Share Dealings

The Company was informed on 5th April 2007 that, pursuant to the Company's recent placing which became effective on the same day, the following directors of the Company purchased in aggregate 3,400,000 ordinary shares of 0.1p each in the Company ("Ordinary Shares") at the placing price of 2.5p per Ordinary Share. The individual purchases and the resulting interests of the directors are set out below:

Director No. of Ordinary Shares Total shareholding % of issued purchased share capital Gwyn Humphreys 2,000,000 13,125,836 1.69 Alastair Smith 400,000 49,617,468 6.38 Simon Webster 200,000 48,824,258 6.28 Kurt Baldwin 200,000 48,824,258 6.28 Tim Sykes 200,000 3,118,718 0.40 Anthony Robards 400,000 8,891,102 1.14Enquiries:Avacta Group plc Tel: 0870 835 4367 Alastair Smith, Chief Executive WH Ireland Limited Tel: 0161 832 2174 David Youngman, Director, Corporate Finance BankOra Limited Tel: 020 7099 1943 Henry Turcan, Director Nexus Financial Ltd Tel: 020 7451 7050 Nicholas Nelson, Director Mob: 07921 522 920 nicholas.nelson@nexusgroup.co.uk10 April 2007

AVACTA GROUP PLC
Date   Source Headline
19th Jul 20163:13 pmRNSHolding(s) in Company
19th Jul 20167:15 amRNSHardman report: New Affimer opportunities
14th Jul 20167:00 amRNSCollaboration with Glythera
8th Jul 20167:00 amRNSDirector/PDMR Shareholding
22nd Jun 20167:00 amRNSAffimer Binders for Zika Virus Diagnostics
16th Jun 201611:08 amRNSIssue of Equity
13th Jun 20167:00 amRNSCollaboration with Mologic
29th Apr 20163:04 pmRNSDirector's Dealing
25th Apr 20167:00 amRNSHalf-year Report
19th Apr 20167:00 amRNSAffimer Therapeutic Platform Development Milestone
7th Apr 20167:00 amRNSDirector's Dealing
5th Apr 20167:00 amRNSInvestor Evening
15th Mar 20167:00 amRNSIssue of Equity
7th Mar 20167:00 amRNSAvacta Establishes Scientific Advisory Board
25th Feb 20164:34 pmRNSHolding(s) in Company
24th Feb 20167:00 amRNSGrant Funding Awarded
23rd Feb 201610:54 amRNSHardman & Co Issues Research Report
23rd Feb 20167:00 amRNSDirector's Dealing
17th Feb 20167:00 amRNSDirectors' Dealings and Issue of Equity
26th Jan 20168:05 amRNSShare Consolidation
25th Jan 20163:35 pmRNSResult of Annual General Meeting
25th Jan 20167:01 amRNSPre-close trading update
25th Jan 20167:00 amRNSPhilippe Cotrel Appointed Chief Commercial Officer
21st Jan 20167:00 amRNSProposed Shareholder Consolidation
7th Jan 20167:00 amRNSPosting of Annual Report & Accounts and AGM Notice
5th Jan 20167:00 amRNSIssue of Equity
10th Dec 20157:00 amRNSAppointment of Tony Gardiner as CFO
1st Dec 20154:44 pmRNSHolding(s) in Company
30th Nov 20157:00 amRNSIssue of Equity
23rd Nov 20157:00 amRNSIssue of Equity
6th Nov 201510:56 amRNSHolding(s) in Company
30th Oct 20157:00 amRNSIssue of Equity
26th Oct 20157:00 amRNSFinal Results
19th Oct 20157:00 amRNSAffimers improve disease resistance in plants
9th Oct 20157:00 amRNSRobust performance of Affimers on Luminex platform
8th Oct 20157:00 amRNSNotice of Results
17th Sep 20157:00 amRNSAppoints Dr Mike Owen as Non-executive Director
10th Sep 20157:00 amRNSTotal Voting Rights
3rd Sep 20157:00 amRNSIssue of Equity
5th Aug 201510:00 amRNSHolding(s) in Company
5th Aug 20157:00 amRNSHolding(s) in Company
4th Aug 201510:18 amRNSIssue of Equity
31st Jul 201510:42 amRNSResult of General Meeting
23rd Jul 20157:00 amRNSIssue of Equity
15th Jul 20157:00 amRNSConditional Placing to Raise up to £22.0 Million
7th Jul 20158:00 amRNSBoard Change
7th Jul 20157:00 amRNSPre-Close Trading Update
20th May 201511:48 amRNSHolding(s) in Company
19th May 201512:42 pmRNSHolding(s) in Company
11th May 20157:00 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.